Friday, May 10, 2019 2:27:42 PM
Link to Annual Report:
https://www.sec.gov/Archives/edgar/data/1314052/000161577418014328/0001615774-18-014328-index.htm
https://www.sec.gov/Archives/edgar/data/1314052/000161577418014328/s114606_10k.htm
Link to Pipeline graphic: https://www.sec.gov/Archives/edgar/data/1314052/000161577418014328/img001_v1.jpg
Mouse PET images: https://www.sec.gov/Archives/edgar/data/1314052/000161577418014328/img002_v1.jpg
PIPELINE
Evolution of the pipeline:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147064606
Results of 4/5/19 shareholder vote:
https://www.sec.gov/Archives/edgar/data/1314052/000161577419005452/s117292_8k.htm
Shareholder rights plan:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145724043
Company website - upcoming and past events:
https://www.anavex.com/investor-material/events/
Company Website - presentations on line:
https://www.anavex.com/investor-material/
Transcript of 12/12/18 Conference call:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145435190
Access to 12/18 Conference call:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145347046
Quick link to SEC filings:
https://fintel.io/filings/us/avxl
Link to SEC filings on EDGAR:
https://www.sec.gov/cgi-bin/browse-edgar?CIK=avxl&owner=exclude&action=getcompany
__________________________________________________________________________________________________________________
SHAREHOLDER'S MEETING NOTES:
Discussion of shareholder's meeting 04/05/19 begins here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148045215
Thanks to our MB, on the scene reporters...
brichnyc, bourbon, and Jonjones325
From bourbon_on_my_cornflakes:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148047383
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148050828
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148058557
From Jonjones325:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148057082
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148057307
From brichnyc:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148084098
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148086244
__________________________________________________________________________________________________________________
RECENT AND UPCOMING PRESENTATIONS, OTHER POSSIBLE EVENTS:
Anavex's SVP of Operations, Stephan Toutain, to speak at the World BI - 13th Clinical Trials Conference, May 7-8 in Boston, MA.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148405784
May 7-8: World BI - 13th Clinical Trials Conference - Boston, MA
Speaker: Stephan Toutain
https://worldbigroup.com/conference/thirteenth-clinical-trials/speakers
June 3-6 : Bio International Convention - Philadelphia, PA
Anavex currently indicated as attending and participating in 1-on-1 Partnering sessions.
https://mybio.org/exhibitor/member/318490
June 4-7 2019, (from kevli33)
Anavex Scientific Advisor attending 5th World Parkinson Congress in Japan.
https://wpc2019.org/page/precongress3
Notes from the above program:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147983117
Missling will speak at the RARE Drug Development Symposium in Philadelphia PA, June 6-7. (from TTav66)
https://globalgenes.org/event/advocacy-symposium/
June 25 : DIA 2019 Global Annual Meeting - San Diego, CA (updated info from TTav66)
Artificial Intelligence Enhanced Data Analytics for Clinical Trials
Panelists: Mohammad Afshar (CEO of Ariana Pharma), and Federico Goodsaid (Principal of Regulatory Pathfinders)
*note: Indication of Dr. Missling's participation was removed at some point after this event was originally shared
https://dia2019globalannualmeeting.sched.com/event/KfWl/245-artificial-intelligence-enhanced-data-analytics-for-clinical-trials
July 23-25 : 2nd Annual NPP ((Neuropsychiatric Drug Development) conference - Boston, MA
- Dr. Missling will lead a workshop; Reviewing the Potential for Precision Medicine in Neurological Diseases on July 23.
- He will also be featured in a 2 person panel with the Executive Director of Neuroscience Discovery at Merck; Panel Discussion: The Precision Medicine Approach to Neuropsychiatry – For or Against? on July 25.
https://npd-summit.com/
Original from TTAV66:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147736866
Possible Catalysts
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145908635
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148107153
Roth panel discussion "Rise and Fall of Amyloid" 3/19:
http://wsw.com/webcast/roth33/panel22/?lobby=true&day=2
A closer look at the Roth Capital Partners Conference Alz panel that Dr Missling is part of (Beyond the Rise and Fall of Amyloid) - (from makemydaze)
https://www.meetmax.com/upload/event_51941/ROTH_2019_Healthcare_Marango_Panel.pdf
Anavex Life Sciences at the Cowen 39th Annual Health Care Conference 2019 Wednesday, March 13
http://wsw.com/webcast/cowen52/avxl/. A replay will be available via www.anavex.com and will be accessible for three months following the presentation.
Feb. 11-12 : BIO CEO & Investor Conference
Presentation
https://www.veracast.com/webcasts/bio/ceoinvestor2019/78204240532.cfm?0.22201266802
Slides only
https://www.anavex.com/wp-content/uploads/2019/02/Anavex-BIO-CEO-Feb-2019-1.pdf
Missling interview:
__________________________________________________________________________________________________________________
AUDIO PRESENTATIONS:
Cantor Fitzgerald Presentation from Cantor Fitzgerald Global Healthcare Conference October 3, 2018 2:50 p.m.
http://wsw.com/webcast/cantor7/avxl/
Comment on the above from dia76ca "At Cantor Dr. Missing said that the Rett trial would "clear VERY SOON"(At the 27:30 minute mark). We would do well to remember some of the other things he said.(e.g. Cash on hand for 2 years...21:21 minute mark ; Anavex 3-71 in clinic in 2019...29:34 minute mark ; Parkinson read-out in 2019...30:40 minute mark."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144349470
Additional audio presentations on the company web site see links at top of post.
___________________________________________________________________________________________________________________
VIDEO PRESENTATIONS
Dr. Harald Hampel, MD, PhD, MA, MSc: Genomic Analysis of ANAVEX 2-73 in Alzheimer Disease Study 10/18, Videos:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148601340
Anavex SAB member Dr Paul Aisen speaks about PET Scans:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143921781
History of rettsyndrome.org featuring Christopher Missling:
Dr. Tangui Maurice on the Sigma 1 - 2015 video:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143980208
Additional video presentations on the company web site see links at top of post.
Videos from UC and Rob Knight (not Anavex specific, but cutting edge science.)
Microbiomes and aging:
https://youtu.be/2iKHMyWzclM
Microbiome mind and brain interaction:
https://www.youtube.com/watch?v=2iKHMyWzclM&t=134s
All of Rob Knight's videos are interesting:
https://www.youtube.com/results?search_query=rob+knight
___________________________________________________________________________________________________________________
SLIDE SHOWS AND POSTERS:
From TTTav: October Corporate Presentation used at the Cantor Fitzgerald Conference
https://www.anavex.com/wp-content/uploads/2018/10/Anavex-Presentation-Oct-2018.pdf
Dr Robert Lisak’s MS poster presented at the 2018 ECTRIMS conference:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144223191&txt2find=ectrims
Anavex 2-73 as a potential treatment for autism spectrum disorders 2016
https://anavex.com/wp-content/uploads/2016-06-06_Poster_AV2-73_Autism_FXS_Conference_June_2016.pdf
Kaufmann presentation 3/27/19
American Society for Experimental Neurotherapeutics - ASENT 2019 Annual Meeting
https://www.anavex.com/wp-content/uploads/2019/03/Anavex-ASENT-March-2019.pdf
https://www.anavex.com/wp-content/uploads/2019/03/Anavex-Presentation-March-2019-1.pdf
Titration could increase the response and efficacy of Anavex 2-73.
A plasma concentration of greater than 4 ng/ml would increase postive responses and efficacy to Anavex 2-73 (from georgejjl)
Slide 10
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147511076
From Slide 27:
What is Actigraphy Monitoring? Mentioned in 3/19 Missling presentation. (from nidan7500)
https://www.verywellhealth.com/what-is-actigraphy-3015130
https://www.actigraphcorp.com/
CTAD 2018 slides - see the following archive
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146087872
___________________________________________________________________________________________________________________
DISCUSSION OF 3/4/19 PAPER ON 2-73 AND AUTOPHAGY:
NEWS!!! March 4, 2019 Third party paper on cellular recycling.
https://www.anavex.com/anavex-life-sciences-reports-publication-of-new-data-that-show-anavex2-73-induces-cellular-recycling-process-linked-to-the-prevention-and-treatment-of-age-associated-diseases/
See autophagy section in the MOA post:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148173528
___________________________________________________________________________________________________________________
POSSIBLE SIGNS OF MOVE TOWARD COMMERCIALIZATION:
Does 2-73 have a name?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146539861
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146540287
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146540557
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146545746
Info on why Anavex needed to spend $1 million on product development in 2018. (from ohsaycanyousee82)
http://www.pharmtech.com/api-sourcing
Discussion of above follows this post:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146733092
___________________________________________________________________________________________________________________
GENERAL TRIAL DISCUSSION AND COMMENTS ON TRIAL PROCEDURE:
Patient Centricity And Social Media Are Changing Patient Recruitment (from Kevli33)
https://www.clinicalleader.com/doc/patient-centricity-and-social-media-are-changing-patient-recruitment-0001
PDD/AD trials in Australia/Spain-Australia and EU can exchange scientific information:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148650906
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148655115
A Brief History of Placebos and Clinical Trials in Psychiatry
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148139761
indialong cites FDA gidance concerning need for placebo in studies:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148154841
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148154913
TempePhil gives us links to all three Anavex trials:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146017758
TTTav66 analysis of trial recruitment and enrollment figures:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145420519
Worst case enrollment figures:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146083304
2-73 preclinical improvement of learning and behavior:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147390935
A clinical trial to validate event-related potential markers of Alzheimer's disease in outpatient settings (from nidan7500)
https://www.dadm.alzdem.com/article/S2352-8729(15)00070-6/fulltext
Will Canada give Conditional Approval if Australia does?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148221699
How enrollment works:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144955802
Precision Medicine and “The Economics of Drug Development”
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144010889
A "sobering read" on precision medicine from Investor2014
https://blogs.sciencemag.org/pipeline/archives/2019/01/31/precision-medicine-real-soon-now
Trial interpretation - What’s in a p value? - a significant read! (from Investor2014)
http://www.evaluate.com/vantage/articles/analysis/vantage-views/whats-p-value
On dosage of 2-73 and P values:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144631198
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144495639
Infantile Spasms Market analysis:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147347329
Rett Syndrome Market Analysis:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147347491
___________________________________________________________________________________________________________________
ALZHEIMER'S DISCUSSIONS :
The economiic impact of dementia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148593001
March 2019 discussion of ACTC begins here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147409548
Discussion on 4/25/19 concerning new blood tests for Alzheimer's - read forward from here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148425843
Alzheimer's biomarkers explained:
https://www.alzdiscovery.org/news-room/blog/alzheimers-biomarkers-explained
On Biomarkers and Surrogate Endpoints. A read forward into the discussion is suggested for additional information on sleep and Alzheimer's:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145241236
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145245388
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145245674
(several posts follow the last link)
Current state of Alzheimer's fluid biomarkers. - Full Paper (from Investor2014)
https://link.springer.com/article/10.1007/s00401-018-1932-x
More on AD and sleep...as predicted... (from nidan7500)
https://alzheimersnewstoday.com/2019/03/15/brains-of-people-with-sleep-apnea-show-higher-burden-of-tau-protein-aggregates
The Alzheimer Precision Medicine Initiative Journal of Alzheimer's disease:
https://content.iospress.com/articles/journal-of-alzheimers-disease/jad181121
Improved Diagnostic for Alzheimer's - just perfect for Anavex 2-73:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148616412
TempePhil analysis of corporate presentations, possible 208 wk data:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148154210
Anti-Tau Trials for Alzheimer’s Disease: A Report from the EU/US/ CTAD Task Force (from Kevli33)
https://www.ctad-alzheimer.com/files/files/Anti-Tau%20trials%20for%20AD%20-%20A%20report%20from%20the%20EU%20US%20CTAD%20Task%20Force.pdf
Basic biology concepts for Alzheimer’s disease
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137348423
The company's stated timeline for Alzheimer's P2b/3:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144956279
Missling states that PET scans will be used in P2/3 trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143981335
P2b/3 dosage slide:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145842885
Blood concentration seems to be important:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147596397
On titration of 2-73:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147635325
Possible partnering for Alzheimer's diagnosis and treatment protocol from tredenwater2
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145766313
U.S. Alzheimer's diagnosis is inferior:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148065564
Will it take 48 weeks to realize these endpoints?
https://investorshub.advfn.com/boards/read_msgs.aspx?board_id=11474&NextStart=178123&BatchSize=20
Possible causes of Alzheimer's summarized:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146243514
Discussion of P2a trial dropouts:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144496759
Missling 2017 comment on blood concentration (from georgejjl):
https://www.mdedge.com/clinicalneurologynews/article/152595/alzheimers-cognition/development-sigma-1-receptor-agonist
Fluoride and Alzheimer's
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147640105
What does Donepezil do?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144744473
How does the body handle Donepezil?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145773592
On the difficulty in diagnosing Alzheimer's:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145129244
Stresses on Caregivers:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147069410
Alzheimer's specific sleep scale:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144847354&txt2find=caregivers
Vitamin D and Alzheimer's:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145586595
Did ACTC consider new biomarkers for this Eisai study?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148730321
AI used to detect Alzheimer's in PET scans (from baltimorebullet)
https://kottke.org/19/01/ai-algorithm-can-detect-alzheimers-earlier-than-doctors
More on Amyloid PET AD diagnostics from Hampel tweet.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146598748
Paper on progression from MCI to Alzhimer's posted by Investor2014 (includes sleep)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762666/
Apoe4 and Alzheimer's
https://medicalxpress.com/news/2016-08-scientists-reveal-people-apoe4-gene.html
https://www.snpedia.com/index.php/APOE
African Americans and Alzheimer's
https://investorshub.advfn.com/boards/read_msgs.aspx?board_id=11474&NextStart=177836&BatchSize=20
French healthcare system decides it will no longer reimburse for Donepezil and other Alzheimer's drugs.
http://english.prescrire.org/en/81/168/55126/0/NewsDetails.aspx
Alzheimer's & SOC - too many patients exposed to drug interactions: French data:
http://english.prescrire.org/en/81/168/49338/0/NewsDetails.aspx
Macfarlane on medication in dementia:
Macfarlane and Hammond Care CEO Stephen Judd on overmedication of elderly patients:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146079150
Could Disposing of Damaged Mitochondria Treat Alzheimer’s Disease? (from Investor2014)
https://www.alzforum.org/news/research-news/could-disposing-damaged-mitochondria-treat-alzheimers-disease
Do we have a good chance to win in the "Oskar Fischer Project" ?
https://alzheimersnewstoday.com/2018/11/09/new-challenge-offers-prize-money-better-understanding-alzheimers/
Might Anavex-facilitated Sleep Prevent Alzheimer’s? (from Falconer66a)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147042424
P300 Amplitude Discussion: See IP section and Partners section
See also insomnia patent under IP, sleep section, and more in ERP in partners section.
Links at the end of this post
___________________________________________________________________________________________________________________
PARKINSON'S DEMENTIA DISCUSSIONS :
January 19 AU governement allocated an additional $36.8 million for Parkinson's research.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148593663
Hammond Care to join in Parkinson's Dementia trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148578140
Trial listing Parkinson's on clinicaltrials.gov as of 12/13/18
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145772074
EU Parkinson's trial info:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144654071
Spanish trial info:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144654240
Parkinson's researchers have asked for an extension:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147933240
http://wsw.com/webcast/cowen52/avxl/
Parkinson's endpoints cognition and motion
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145688901
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145689920
Spanish info on Parkinson's trial as of 2/26/19
http://www.gacetamedica.com/especializada/comienza-la-segunda-fase-del-estudio-clinico-para-enfermedad-de-parkinson-con-demencia-asociada-MG1945349
English Translation:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147248343
How the Parkinson's Dementia trial may help expedite Alzheimer's approval:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143580569
More on Parkinson's and sleep (from nidan7500):
https://parkinsonsnewstoday.com/2019/03/13/study-factors-sleep-benefit-parkinsons-disease/
Biostockclub on Parkinson's dosage:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144533102
Scientists Are Warning of a Future Parkinson's Pandemic, And We Can't Ignore It (from Amateur17)
https://www.sciencealert.com/research-warns-of-a-pending-parkinson-s-pandemic-and-we-need-to-pay-attention
Parkinson's News Today announces trial with participation of MJF foundation from whippensaw:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144653898
Sleep in Parkinson's disease -
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145233486
From K9uwa aka John: Today in Parkinsons News Today ENROLLING NOW in Spain article.
http://parkinsonsnewstoday.com/2018/11/01/anavex-recruiting-parkinsons-dementia-patients-spain-anavex-2-73-trial/
Testing method to be used:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145428524
Dr. M. Angela Cenci Nilsson resulting study from the 2015 research grant
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148339012
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148342120
PROFILE
http://www.academia-net.org/profil/prof-dr-m-angela-cenci-nilsson/1488381
Veronica Francardo
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148342376
Francardo May 2018 statement on effect of 2-73 in Parkinson's
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134044839
Anavex PR's from the Lund preclinical research on Parkinson's by Cenci-Nilsson and Francardo.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148343391
___________________________________________________________________________________________________________________
RETT SYNDROME DISCUSSION :
Video of Rett Syndrome Kids (from kevli 33)
Australian Rett Syndrom Trial starts May 9 2019 (from Greenspam3)
https://www.facebook.com/rettaustralia/
https://www.anavex.com/rett-syndrome-association-of-australia-and-anavex-life-sciences-announce-initiation-of-the-phase-2-avatar-clinical-study-in-patients-with-rett-syndrome/
On Missling's plan for Rett Trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148732543
"RettSyndrome.org updated their Clinical Trials information on 4/4/19 with the link below.
This will give the Rett Families a bit more information and encourage trial participation."
(Quoted and provided by Talon38)
https://www.rettsyndrome.org/file/press-releases/Anavex-doses-1st-Patient.pdf
Trial listing Rett Syndrome on clinicaltrials.gov as of 12/07/18
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145772107
Rett Syndrome prospects, trial update, and patent (from georgejjl )
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146683698
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146684425
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146720630
ANAVEX 2-73 Normalizes Hippocampal BDNF Expression
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148132992
For the first time a human disease — Rett Syndrome, the first identified epigenetic disease — has been linked to specific defects in the three-dimensional folding of chromatin. (from georgejjl)
https://www2.lbl.gov/Science-Articles/Archive/LSD-Rett-syndrome.html
see also:
https://www2.lbl.gov/Science-Articles/Archive/assets/images/2004/Dec-20/DLX5-Rett-Syndrome.pdf
Epigenomics and Rett Syndrome:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147643763
On the ambiguity in earnings call on Rett trials:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146678488
Response from runcoach:
https://investorshub.advfn.com/boards/replies.aspx?msg=146678488
FDA Revising ‘Draft Guidance’ on Developing Treatments for Rare Diseases (from nidan7500)
https://rettsyndromenews.com/2019/01/30/fda-revising-draft-guidance-on-developing-treatments-for-rare-diseases/
Levetiracetam possible for Alzheimer's
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147247821
Anavex 2-73 synergism with levetiracetam for treatment of Rett syndrome and epilepsy.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147246715
Rett syndrome testing via auditory event:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146263432
Rettsyndromenews.com on the 2-73 trial
https://rettsyndromenews.com/2019/01/08/phase-2-trial-anavex-2-73-rett-syndrome/
Anavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX®2-73 in Patients with Rett Syndrome
Study will incorporate genomic precision medicine ANAVEX®2-73-specific biomarkers
https://www.anavex.com/anavex-life-sciences-announces-fda-approval-of-ind-for-phase-2-trial-of-anavex2-73-in-patients-with-rett-syndrome/
Rett Syndrome trial and endpoints announced on Clinicaltrials.gov 11/29/18 (Thanks to poster Abel and Cabel)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145164109
Info on Dr. Kaufmann who will be running the 2-73 Rett Syndrome trial and who is now CMO for Anavex:
http://gcbcenter.kennedykrieger.org/staff.jsp
2016 presentation on Rett Syndrome
https://anavex.com//wp-content/uploads/ANAVEX-2-73-as-a-Potential-Treatment-for-Rett-Syndrome.pdf
2017 presentation on Rett Syndrome
Rett Syndrome in adults:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145216562
http://www.anavex.com/wp-content/uploads/2017/05/Anavex-Angelman-FX-Rett-conference-update-2017-May-2017-final.pdf
Rett Syndrome & Fragile x - they are are related:
From Talon38 (post 173314) "NIH's updated (2 days ago) information on Fragile X. Notice both the similarities and differences (predominantly a male diseases). Fragile X is one of 2-73's pipeline targets as is Infantile Spasms and Angelman's. Not a stretch to believe that Tayo Fadiran has been working CDER and NIH for a combined clinical trial approach to these orphan diseases. With positive Rett Syndrome results, that may come to fruition. The 2-73 "train" is gathering momentum!"
https://ghr.nlm.nih.gov/condition/fragile-x-syndrome
Rett Syndrome Study Design a link Natural History Study Publications from Investor2014:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144701675
https://www.rettsyndrome.org/for-researchers/nhs-research-publications
Discussion of Rett Trial Design why it is structured the way it is:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144356675
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145205166
On the disease phases of Rett Syndrome:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144701046
Will the trial be moved to Australia?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144362026
On Rett Syndrome and the M4 Receptor from Investor2014:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144347886
Other Rett Syndrome related posts:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144357506
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135703149
Disturbed redox homeostasis and oxidative stress: Potential players in the developmental regression in Rett syndrome
https://www.sciencedirect.com/science/article/pii/S0149763418306900 (from Investor2014)
Talon38 provided this NIH link on Rett Syndrome:
https://ghr.nlm.nih.gov/condition/rett-syndrome
dadofmarcmax on Rett Syndrome and other epileptic diseases:
see CNS ADDITiONAL INDICATIONS below
Paper on Rett Syndrome treatment procedures:
https://pdfs.semanticscholar.org/c2c8/1063888a7aecffd3b1fe74a7b67496b2554f.pdf
___________________________________________________________________________________________________________________
EPILEPSY DISCUSSION:
Question of Epilepsy parnership:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147238816
PennyDouble reminds us, we have an expert on the SAB :
https://www.anavex.com/anavex-life-sciences-appoints-distinguished-researcher-neurology-epilepsy-scientific-advisory-board/
The significance of adding Dr Andrew Cole MD authority on Epilepsy to Anavex SAB:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144358640
___________________________________________________________________________________________________________________
FRAGILE X DISCUSSION:
Fragile X syndrome connected to mitochondrial dysfunction. (from Steady_T)
https://medicalxpress.com/news/2019-02-cell-component-breakdown-treatment-multiple.html
Fragile X is a growing concern (link from cninc):
https://www.frontiersin.org/articles/10.3389/fpsyt.2018.00564/full
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144971728
Will fragile x start trials soon?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146687514
Anavex 2-73 and the autism market:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147237001&txt2find=2016
Kaufmann paper on FragileX and Autism:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148178337
___________________________________________________________________________________________________________________
MULTIPLE SCLEROSIS DISCUSSION:
Dr Lisak's preclinical of 2-73 in MS:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147244571
MS - needs more scientific development in order to support a successful 2-73 trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145845309
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145855079
Youtubes on Myelin:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145846058
MS is still on the table per 12/12/18 10K
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146069570
MS and gender bias
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145789105
Anavex - Biogen & MS
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135630393
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143729928
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143732818
https://investorshubAL.advfn.com/boards/read_msg.aspx?message_id=143734046
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144040837
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143735763
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147244426
___________________________________________________________________________________________________________________
SCHIZOPHRENIA DISCUSSION :
Crosstalk between endoplasmic reticulum stress and oxidative stress in schizophrenia: The dawn of new therapeutic approaches.
(link from georgejjl)
https://www.ncbi.nlm.nih.gov/pubmed/28890198
see also:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461562/
___________________________________________________________________________________________________________________
OTHER CNS & ADDITIONAL INDICATIONS:
From dadofmarcmax, the linked site has TONS of info:
"Why does Anavex 2-73 have effects on seemingly different neuro-degenerative disorders? What makes it so special? "
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143816865
Falconer on commonalities of CNS disease:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145055598
Anavex 2-73 and/or 3-71 as a treatment for postpartum depression
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144995494&txt2find=71
A2-73 mixed S1R and Muscarinic modulation - not just S1R. (from Investor2014)
Citation from this paper: https://www.google.co.uk/amp/s/www.researchgate.net/publication/11175896_AF150S_and_AF267B_-_M1_muscarinic_agonists_as_innovative_therapies_for_Alzheimer's_disease/amp
Alzheimer’s and Parkinson’s Disease: Similarities and Differences (Aarsland and Weintraub have AVXL affiliation)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147932208
Autophagy and mitophagy in ALS.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147418161
Angelman Syndrome:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147200990
dadofmarcmax on treatment of epilepsy with Anavex platform drugs:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=127872231
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=131111781
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144438361
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135019599
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135028269
A2-73 for macular degeneration
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148342276
Huntington's Disease and aging mitochondria:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145684759
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145684899
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145685427
Diabetic market:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145572335
Psychiatric disease:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145559580
Normalization of hypertension - peer reviewed in January 2018
https://www.anavex.com/anavex-life-sciences-reports-potential-normalization-of-hypertension-with-anavex2-73-published-in-the-journal-of-clinical-hypertension/
Causes of CVD, mitochondrial dysfunction, oxidative stress and neuroinflamation:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146829394
Anavex 2-73 and/or Anavex 3-71 could be used to treat TBI Traumatic Brain Injury
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145739701
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147181730
Anavex also has Orphan Drug Designation for Infantile Spasms:
https://www.anavex.com/anavex-announces-u-s-fda-orphan-drug-designation-for-anavex-2-73-for-treatment-of-infantile-spasms/
Crosstalk between endoplasmic reticulum stress and oxidative stress in schizophrenia: The dawn of new therapeutic approaches.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147699893
The emerging roles of protein homeostasis-governing pathways in Alzheimer's disease.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147703240
___________________________________________________________________________________________________________________
MISC. DISCUSSIONS:
Falconer taking the temperature of the medical research community:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148589256
2015 mention of ERP results at five weeks:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148130307
Anavex 2-73 might show better results with younger patients than older patients.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148058285
2015 new discovery about the brain and the immune system:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148062119
“Enabling precision medicine with integrated genomic and clinical data” posted by Harald Hampel and kevli33
https://twitter.com/harald_hampel/status/1114590967531753472?s=21
https://azure.microsoft.com/en-us/blog/enabling-precision-medicine-with-integrated-genomic-and-clinical-data/
Anavex is not just a drug company - opinion from Lima4918
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147759921
Old brains and neurogenesis (from powerwalker).
https://www.statnews.com/2019/03/25/old-brains-make-new-neurons-possibly-protecting-against-alzheimers/
Top 20 CNS drug companies:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147869585
A new urgency for Expanded Access:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147906853
An excellent summary of why we are here from poster sokol:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143320176
Sokol on Anavex's international strategies:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144504285
Link to PeterKarol's blog:
https://piotrpeterblog.com/
Scientists rise up against statistical significance (from Biostockclub)
https://www.nature.com/articles/d41586-019-00857-9
Life expectancy in the US still continues to go down, 2018 graphic:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147424525
Short term milestone summary:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144330988
Comment on industry trends (link from PennyDouble)
https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/us-and-global-life-sciences-industry-trends-outlook.html
Protein degradation disease treatments:
https://www.investors.com/news/technology/protein-degradation-eyed-pharmaceutical-companies-drug-development/
AI estimates brain age:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147255249
Orphan Disease Designation in Rett and Infantile Spasm
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146540508
Expansion of rare disease diagnostic codes (from nidan7500)
https://dravetsyndromenews.com/2019/02/04/icd-10-codes-really-important-to-rare-disease-patients-soon-up-for-fresh-consideration/
Missling has a strategy - comments from posters on that strategy:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144051610
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144350599
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145164402
Personal comments from falconer66a on the failure of traditional western medicine:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144979916
How the U.S. is failing its people in healthcare:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145076878
Brain cells from stem cells at Lund University:
https://www.lunduniversity.lu.se/article/new-method-grows-brain-cells-from-stem-cells-quickly-and-efficiently
Sokol with a 2016 perspective on potential Alzheimer's treatments:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144809093
2018 Shareholder meeting report:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140128467
___________________________________________________________________________________________________________________
BIG PHARMA AND POTENTIAL PARTNER DISCUSSION:
The “next wave” of BP’s being incubated now, in the form of small, smart, faster biotechs! 4/23/19 article:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148381829
Merck and 21st Century Medicine
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148109429
Merck and the Canadians team up:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148108335
https://www.eurekalert.org/pub_releases/2017-03/mu-npt031717.php
Roche and Genentech - a case study:
https://knowledge.wharton.upenn.edu/article/anatomy-of-a-merger-hostile-deals-become-friendly-in-the-end-right/
Why modern medicine is like the medieval church:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146539971
Below is a link to a 6-part article that shines a bright light on big pharma's influence in the market, research and fake news... rather revealing! (from basparks79)
https://articles.mercola.com/sites/articles/archive/2017/12/27/drug-safety-media-shaped-by-big-pharma.aspx
BIIB's problem with their Alzheimer's trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144801572
Bayer also bailing on R&D:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145174145
Why did Big Pharma bail on Alzheimer's trials early 2018? Possible Answer:
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM596728.pdf
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145205259
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145214094
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145215823
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145214295
(see also MS section above)
___________________________________________________________________________________________________________________
TRIAL PROCEDURE:
U.S. FDA: 04/23/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148386035
AUSTRALIA'S TGA: 05/10/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148738081
OTHER COUNTRIES: 05/10/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148741442
___________________________________________________________________________________________________________________
LINKS TO OTHER SECTIONS:
IP Protection:05/10/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148741585
AVXL -The Stock and the Market 05/10/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148741272
Genetic issues- sex and more 05/10/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148740737
SLEEP 05/10/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148740357
MOA and MEDICAL SCIENCE DISCUSSION 05/10/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148740172
GUT and BRAIN - barrier and permeability 05/10/19
https://investorshub.advfn.com/boards/edit_msg.aspx?message_id=148739064
Anavex Partners 05/10/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148740825
The People of Anavex 5/09/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148384976
3-71 Discussion 04/11/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148170998
Elder Care Crisis:03/04/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147273055
PRESS AND THIRD PARTY 03/17/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147597266
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM